$NKTR
NEKTAR THERAPEUTICS

2023 Q3 Form 10-Q Financial Statement

#000090670923000012 Filed on August 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $24.14M $20.50M
YoY Change 2.2% -5.03%
Cost Of Revenue $12.43M $6.994M
YoY Change 150.02% 36.74%
Gross Profit $11.71M $13.51M
YoY Change -37.21% -18.0%
Gross Profit Margin 48.51% 65.88%
Selling, General & Admin $21.10M $17.87M
YoY Change -6.36% -16.67%
% of Gross Profit 180.14% 132.31%
Research & Development $24.07M $29.68M
YoY Change -28.34% -30.55%
% of Gross Profit 205.5% 219.78%
Depreciation & Amortization $1.700M $2.166M
YoY Change -36.5% -37.05%
% of Gross Profit 14.51% 16.04%
Operating Expenses $24.07M $29.68M
YoY Change -28.34% -30.55%
Operating Profit -$44.86M -$50.60M
YoY Change -17.38% -66.89%
Interest Expense -$1.000M -$570.0K
YoY Change -79.6% -90.7%
% of Operating Profit
Other Income/Expense, Net -$1.034M -$570.0K
YoY Change -78.91% -90.7%
Pretax Income -$45.90M -$51.17M
YoY Change -22.47% -67.81%
Income Tax -$61.00K -$47.00K
% Of Pretax Income
Net Earnings -$45.84M -$51.12M
YoY Change -22.37% -67.86%
Net Earnings / Revenue -189.85% -249.39%
Basic Earnings Per Share -$0.24 -$0.27
Diluted Earnings Per Share -$0.24 -$0.27
COMMON SHARES
Basic Shares Outstanding 190.1M shares 189.2M shares
Diluted Shares Outstanding 190.4M 189.7M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $372.7M $409.4M
YoY Change -31.8% -33.89%
Cash & Equivalents $64.92M $50.73M
Short-Term Investments $307.7M $358.7M
Other Short-Term Assets $9.033M $9.602M
YoY Change -59.87% -50.11%
Inventory $15.13M $20.69M
Prepaid Expenses
Receivables $2.204M $1.335M
Other Receivables $0.00 $0.00
Total Short-Term Assets $399.0M $441.1M
YoY Change -33.44% -33.73%
LONG-TERM ASSETS
Property, Plant & Equipment $19.95M $22.55M
YoY Change -45.8% -43.32%
Goodwill $0.00 $0.00
YoY Change -100.0% -100.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.523M $1.652M
YoY Change 94.71% -26.05%
Total Long-Term Assets $43.22M $53.22M
YoY Change -76.19% -72.91%
TOTAL ASSETS
Total Short-Term Assets $399.0M $441.1M
Total Long-Term Assets $43.22M $53.22M
Total Assets $442.2M $494.3M
YoY Change -43.38% -42.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.288M $2.619M
YoY Change -38.3% -78.79%
Accrued Expenses $29.73M $29.14M
YoY Change -62.21% -68.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $52.11M $50.69M
YoY Change -37.95% -51.71%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.961M $5.151M
YoY Change 62.44% 147.64%
Total Long-Term Liabilities $4.961M $5.151M
YoY Change 62.44% 147.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $52.11M $50.69M
Total Long-Term Liabilities $4.961M $5.151M
Total Liabilities $282.9M $297.3M
YoY Change -23.29% -26.27%
SHAREHOLDERS EQUITY
Retained Earnings -$3.435B -$3.389B
YoY Change 9.35% 9.96%
Common Stock $3.601B $3.593B
YoY Change 1.09% 1.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $159.4M $197.0M
YoY Change
Total Liabilities & Shareholders Equity $442.2M $494.3M
YoY Change -43.38% -42.66%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$45.84M -$51.12M
YoY Change -22.37% -67.86%
Depreciation, Depletion And Amortization $1.700M $2.166M
YoY Change -36.5% -37.05%
Cash From Operating Activities -$42.20M -$51.52M
YoY Change -49.09% -31.3%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $162.0K
YoY Change -100.0% -120.77%
Acquisitions
YoY Change
Other Investing Activities $56.40M $25.33M
YoY Change -49.45% -70.17%
Cash From Investing Activities $56.40M $25.17M
YoY Change -49.37% -70.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 18.00K
YoY Change -96.15%
NET CHANGE
Cash From Operating Activities -42.20M -51.52M
Cash From Investing Activities 56.40M 25.17M
Cash From Financing Activities 0.000 18.00K
Net Change In Cash 14.20M -26.33M
YoY Change -50.19% -373.69%
FREE CASH FLOW
Cash From Operating Activities -$42.20M -$51.52M
Capital Expenditures $0.00 $162.0K
Free Cash Flow -$42.20M -$51.69M
YoY Change -48.98% -30.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0000906709
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-24006
dei Entity Registrant Name
EntityRegistrantName
NEKTAR THERAPEUTICS
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3134940
dei Entity Address Address Line1
EntityAddressAddressLine1
455 Mission Bay Boulevard South
dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94158
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
482-5300
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
NKTR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
190118673 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50728000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88227000 usd
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
358704000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
416750000 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1335000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5981000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
20689000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
19202000 usd
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
9602000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
15808000 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
441058000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
545968000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22554000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32451000 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
29015000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
710600000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
53435000 usd
CY2023Q2 us-gaap Goodwill
Goodwill
0 usd
CY2022Q4 us-gaap Goodwill
Goodwill
76501000 usd
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1652000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2245000 usd
CY2023Q2 us-gaap Assets
Assets
494279000 usd
CY2022Q4 us-gaap Assets
Assets
710600000 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2619000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12980000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
29142000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36557000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
18933000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
18667000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
50694000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
68204000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
105817000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
112829000 usd
CY2023Q2 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
135659000 usd
CY2022Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
155378000 usd
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5151000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7551000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
297321000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
343962000 usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0 shares
CY2023Q2 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
190119000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
190119000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
188560000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
188560000 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
19000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
19000 usd
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3592722000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3574719000 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6450000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6907000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3389333000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3201193000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
196958000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
366638000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
494279000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20499000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21585000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
42093000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
46407000 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6994000 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5115000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14054000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
10430000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29681000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42740000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60150000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
149993000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17869000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20521000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38950000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
47860000 usd
CY2023Q2 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
16554000 usd
CY2022Q2 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
106045000 usd
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
37747000 usd
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
107520000 usd
CY2023Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2022Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76501000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
71098000 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
174421000 usd
us-gaap Costs And Expenses
CostsAndExpenses
227402000 usd
us-gaap Costs And Expenses
CostsAndExpenses
315803000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-50599000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-152836000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-185309000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-269396000 usd
CY2023Q2 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0 usd
CY2022Q2 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
33427000 usd
CY2023Q2 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
6152000 usd
CY2022Q2 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
7228000 usd
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
12557000 usd
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
14757000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5582000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1096000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9616000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1491000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-570000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6132000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2941000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
20161000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-51169000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-158968000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-188250000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-249235000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-47000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-110000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
226000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-51122000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-159068000 usd
us-gaap Net Income Loss
NetIncomeLoss
-188140000 usd
us-gaap Net Income Loss
NetIncomeLoss
-249461000 usd
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.99
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.99
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.34
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
189656000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
189656000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
186800000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
186800000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
189268000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
189268000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
186323000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
186323000 shares
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-51122000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-159068000 usd
us-gaap Net Income Loss
NetIncomeLoss
-188140000 usd
us-gaap Net Income Loss
NetIncomeLoss
-249461000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
244000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-988000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1331000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-3079000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1013000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-671000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-874000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-955000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-769000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1659000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
457000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4034000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51891000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-160727000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-187683000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-253495000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
679508000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
188000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20961000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-92768000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
607889000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
467000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11103000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-160727000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
458732000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
366638000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
0 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10019000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-135792000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
240865000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
18000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7966000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51891000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
196958000 usd
us-gaap Profit Loss
ProfitLoss
-188140000 usd
us-gaap Profit Loss
ProfitLoss
-249461000 usd
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
32693000 usd
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
33825000 usd
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
12557000 usd
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
14757000 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
33427000 usd
nktr Non Cash Research And Development Expense
NonCashResearchAndDevelopmentExpense
0 usd
nktr Non Cash Research And Development Expense
NonCashResearchAndDevelopmentExpense
4951000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17985000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32064000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4468000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
7171000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1839000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
26455000 usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
57321000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76501000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
8150000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-700000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4646000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-12486000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1487000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1168000 usd
nktr Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
3717000 usd
nktr Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
-1486000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-7902000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-7627000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-9997000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2833000 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-7929000 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
13068000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-103438000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-163417000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
249724000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
247014000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
316088000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
466423000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
595000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4983000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
65769000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
214426000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
18000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
655000 usd
us-gaap Proceeds From Derivative Instrument Financing Activities
ProceedsFromDerivativeInstrumentFinancingActivities
0 usd
us-gaap Proceeds From Derivative Instrument Financing Activities
ProceedsFromDerivativeInstrumentFinancingActivities
750000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1405000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
152000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-87000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-37499000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
52327000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88227000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25218000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50728000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77545000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2656000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
85000 usd
CY2023Q2 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
409400000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Significant ConcentrationsOur customers are primarily pharmaceutical companies that are located in the U.S. and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. <div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, various factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we </span></div>may sell securities before maturity if the issuer’s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if various factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.
CY2022Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2023Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50728000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88227000 usd
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
358704000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
416750000 usd
CY2023Q2 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
409432000 usd
CY2022Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
504977000 usd
CY2023Q2 us-gaap Cash
Cash
12131000 usd
CY2022Q4 us-gaap Cash
Cash
8798000 usd
CY2023Q2 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
409432000 usd
CY2022Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
504977000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1800000 usd
CY2023Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2045000 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2575000 usd
CY2023Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
12879000 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
10749000 usd
CY2023Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5765000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5878000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
20689000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
19202000 usd
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
9602000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
15808000 usd
CY2023Q2 nktr Depreciable Property Plant And Equipment Gross
DepreciablePropertyPlantAndEquipmentGross
129730000 usd
CY2022Q4 nktr Depreciable Property Plant And Equipment Gross
DepreciablePropertyPlantAndEquipmentGross
154652000 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
107637000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
124731000 usd
CY2023Q2 nktr Depreciable Property Plant And Equipment Net
DepreciablePropertyPlantAndEquipmentNet
22093000 usd
CY2022Q4 nktr Depreciable Property Plant And Equipment Net
DepreciablePropertyPlantAndEquipmentNet
29921000 usd
CY2023Q2 us-gaap Construction In Progress Gross
ConstructionInProgressGross
461000 usd
CY2022Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
2530000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22554000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32451000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
76501000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76501000 usd
CY2023Q2 us-gaap Goodwill
Goodwill
0 usd
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76500000 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10670000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9582000 usd
CY2023Q2 nktr Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
5517000 usd
CY2022Q4 nktr Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
12262000 usd
CY2023Q2 nktr Liability To Collaboration Partners Current
LiabilityToCollaborationPartnersCurrent
4472000 usd
CY2022Q4 nktr Liability To Collaboration Partners Current
LiabilityToCollaborationPartnersCurrent
3808000 usd
CY2023Q2 nktr Accrued Contract Termination Costs Current
AccruedContractTerminationCostsCurrent
3084000 usd
CY2022Q4 nktr Accrued Contract Termination Costs Current
AccruedContractTerminationCostsCurrent
3902000 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5399000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7003000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
29142000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36557000 usd
CY2022Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
155378000 usd
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
32693000 usd
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
12557000 usd
nktr Liabilities On Sale Of Future Royalties Amortized Transaction Costs
LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts
417000 usd
CY2023Q2 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
135659000 usd
CY2023Q2 us-gaap Litigation Reserve
LitigationReserve
0 usd
CY2022Q4 us-gaap Litigation Reserve
LitigationReserve
0 usd
CY2022Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
0 usd
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
52200000 usd
CY2022Q2 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
52200000 usd
CY2022Q2 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
52201000 usd
CY2022Q2 nktr Impairment Long Lived Asset Held For Use Other
ImpairmentLongLivedAssetHeldForUseOther
5120000 usd
CY2022Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
57321000 usd
CY2023Q1 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
11500000 usd
CY2023Q1 nktr Impairment Long Lived Asset Held For Use Other
ImpairmentLongLivedAssetHeldForUseOther
1700000 usd
CY2023Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
13300000 usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
26500000 usd
CY2023Q2 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
13255000 usd
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
24755000 usd
nktr Impairment Long Lived Asset Held For Use Other
ImpairmentLongLivedAssetHeldForUseOther
1700000 usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
26455000 usd
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76500000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7966000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11103000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17985000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32064000 usd

Files In Submission

Name View Source Status
0000906709-23-000012-index-headers.html Edgar Link pending
0000906709-23-000012-index.html Edgar Link pending
0000906709-23-000012.txt Edgar Link pending
0000906709-23-000012-xbrl.zip Edgar Link pending
ar2017performanceincentive.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nektarlogoa.jpg Edgar Link pending
nktr-20230630.htm Edgar Link pending
nktr-20230630.xsd Edgar Link pending
nktr-20230630_def.xml Edgar Link unprocessable
nktr-20230630_cal.xml Edgar Link unprocessable
nktr-20230630_lab.xml Edgar Link unprocessable
nktr-20230630_pre.xml Edgar Link unprocessable
nktr-20230630_htm.xml Edgar Link completed
nktr2023-06x30xexx311.htm Edgar Link pending
nktr2023-06x30xexx312.htm Edgar Link pending
nktr2023-06x30xexx321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
thomsenemploymentseparatio.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable